Eventide Asset Management’s Epizyme, Inc EPZM Stock Holding History

Eventide Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-275,000	Closed	-$5.24M	–	147
2017 Q3	$5.24M	Hold	275,000	–	–	0.3%	75
2017 Q2	$4.15M	Hold	275,000	–	–	0.26%	77
2017 Q1	$4.72M	Hold	275,000	–	–	0.31%	73
2016 Q4	$3.33M	Hold	275,000	–	–	0.22%	84
2016 Q3	$2.71M	Hold	275,000	–	–	0.17%	89
2016 Q2	$2.82M	Hold	275,000	–	–	0.17%	88
2016 Q1	$3.33M	Buy	+275,000	New	+$2.78M	0.19%	87

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Eventide Asset Management's EPZM Position: Q4 2017 in Review

Eventide Asset Management sold out of Epizyme, Inc (EPZM) in Q4 2017, closing a stake of 275,000 shares — an estimated $5.24M sold.

Eventide Asset Management first reported a position in EPZM in Q1 2016 and held it in 7 quarters. The position peaked at $5.24M in Q3 2017. 101 funds tracked by Wall St. Rank hold EPZM as of Q4 2017.

Eventide Asset Management reported no remaining Epizyme, Inc position as of Q4 2017 after selling out during the quarter.
Eventide Asset Management sold 275,000 Epizyme, Inc shares in Q4 2017, an estimated $5.24M.
Eventide Asset Management first reported a position in Epizyme, Inc in Q1 2016 and held it in 7 quarters.
Eventide Asset Management's Epizyme, Inc position peaked at $5.24M in Q3 2017.
101 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2017.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.